Skip to main content
Erschienen in: Diabetologia 3/2018

05.01.2018 | Short Communication

IFN-α induces a preferential long-lasting expression of MHC class I in human pancreatic beta cells

verfasst von: Alexandra Coomans de Brachène, Reinaldo S. Dos Santos, Laura Marroqui, Maikel L. Colli, Lorella Marselli, Raghavendra G. Mirmira, Piero Marchetti, Decio L. Eizirik

Erschienen in: Diabetologia | Ausgabe 3/2018

Einloggen, um Zugang zu erhalten

Abstract

Aims/hypothesis

IFN-α, a cytokine expressed in human islets from individuals affected by type 1 diabetes, plays a key role in the pathogenesis of diabetes by upregulating inflammation, endoplasmic reticulum (ER) stress and MHC class I overexpression, three hallmarks of islet histology in early type 1 diabetes. We tested whether expression of these mediators of beta cell loss is reversible upon IFN-α withdrawal or IFN-α pathway inhibition.

Methods

IFN-α-induced MHC class I overexpression, ER stress and inflammation were evaluated by flow cytometry, immunofluorescence and real-time PCR in human EndoC-βH1 cells or human islets exposed to IFN-α with or without the presence of Janus kinase (JAK) inhibitors. Protein expression was evaluated by western blot.

Results

IFN-α-induced expression of inflammatory and ER stress markers returned to baseline after 24–48 h following cytokine removal. In contrast, MHC class I overexpression at the cell surface persisted for at least 7 days. Treatment with JAK inhibitors, when added with IFN-α, prevented MHC class I overexpression, but when added 24 h after IFN-α exposure these inhibitors failed to accelerate MHC class I return to baseline.

Conclusions/interpretation

IFN-α mediates a long-lasting and preferential MHC class I overexpression in human beta cells, which is not affected by the subsequent addition of JAK inhibitors. These observations suggest that IFN-α-stimulated long-lasting MHC class I expression may amplify beta cell antigen presentation during the early phase of type 1 diabetes and that IFN-α inhibitors might need to be used at very early stages of the disease to be effective.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Richardson SJ, Rodriguez-Calvo T, Gerling IC et al (2016) Islet cell hyperexpression of HLA class I antigens: a defining feature in type 1 diabetes. Diabetologia 59:2448–2458CrossRefPubMedPubMedCentral Richardson SJ, Rodriguez-Calvo T, Gerling IC et al (2016) Islet cell hyperexpression of HLA class I antigens: a defining feature in type 1 diabetes. Diabetologia 59:2448–2458CrossRefPubMedPubMedCentral
2.
Zurück zum Zitat Foulis AK, Farquharson MA, Meager A (1987) Immunoreactive alpha-interferon in insulin-secreting beta cells in type 1 diabetes mellitus. Lancet 2:1423–1427CrossRefPubMed Foulis AK, Farquharson MA, Meager A (1987) Immunoreactive alpha-interferon in insulin-secreting beta cells in type 1 diabetes mellitus. Lancet 2:1423–1427CrossRefPubMed
3.
Zurück zum Zitat Bending D, Zaccone P, Cooke A (2012) Inflammation and type 1 diabetes. Int Immunol 24:339–346CrossRefPubMed Bending D, Zaccone P, Cooke A (2012) Inflammation and type 1 diabetes. Int Immunol 24:339–346CrossRefPubMed
4.
Zurück zum Zitat Marroqui L, Dos Santos RS, Op de Beeck A et al (2017) Interferon-alpha mediates human beta cell HLA class I overexpression, endoplasmic reticulum stress and apoptosis, three hallmarks of early human type 1 diabetes. Diabetologia 60:656–667CrossRefPubMed Marroqui L, Dos Santos RS, Op de Beeck A et al (2017) Interferon-alpha mediates human beta cell HLA class I overexpression, endoplasmic reticulum stress and apoptosis, three hallmarks of early human type 1 diabetes. Diabetologia 60:656–667CrossRefPubMed
5.
Zurück zum Zitat Marroqui L, Dos Santos RS, Floyel T et al (2015) TYK2, a candidate gene for type 1 diabetes, modulates apoptosis and the innate immune response in human pancreatic beta-cells. Diabetes 64:3808–3817CrossRefPubMed Marroqui L, Dos Santos RS, Floyel T et al (2015) TYK2, a candidate gene for type 1 diabetes, modulates apoptosis and the innate immune response in human pancreatic beta-cells. Diabetes 64:3808–3817CrossRefPubMed
7.
Zurück zum Zitat Kallionpaa H, Elo LL, Laajala E et al (2014) Innate immune activity is detected prior to seroconversion in children with HLA-conferred type 1 diabetes susceptibility. Diabetes 63:2402–2414CrossRefPubMed Kallionpaa H, Elo LL, Laajala E et al (2014) Innate immune activity is detected prior to seroconversion in children with HLA-conferred type 1 diabetes susceptibility. Diabetes 63:2402–2414CrossRefPubMed
8.
Zurück zum Zitat Ferreira RC, Guo H, Coulson RM et al (2014) A type I interferon transcriptional signature precedes autoimmunity in children genetically at risk for type 1 diabetes. Diabetes 63:2538–2550CrossRefPubMedPubMedCentral Ferreira RC, Guo H, Coulson RM et al (2014) A type I interferon transcriptional signature precedes autoimmunity in children genetically at risk for type 1 diabetes. Diabetes 63:2538–2550CrossRefPubMedPubMedCentral
9.
Zurück zum Zitat Fromm SV, Ehrlich R (2001) IFN-gamma affects both the stability and the intracellular transport of class I MHC complexes. J Interf Cytokine Res 21:199–208CrossRef Fromm SV, Ehrlich R (2001) IFN-gamma affects both the stability and the intracellular transport of class I MHC complexes. J Interf Cytokine Res 21:199–208CrossRef
10.
11.
Zurück zum Zitat Freudenburg W, Gautam M, Chakraborty P et al (2013) Immunoproteasome activation during early antiviral response in mouse pancreatic beta-cells: new insights into auto-antigen generation in type 1 diabetes? J Clin Cell Immunol 4:141CrossRefPubMedPubMedCentral Freudenburg W, Gautam M, Chakraborty P et al (2013) Immunoproteasome activation during early antiviral response in mouse pancreatic beta-cells: new insights into auto-antigen generation in type 1 diabetes? J Clin Cell Immunol 4:141CrossRefPubMedPubMedCentral
12.
Metadaten
Titel
IFN-α induces a preferential long-lasting expression of MHC class I in human pancreatic beta cells
verfasst von
Alexandra Coomans de Brachène
Reinaldo S. Dos Santos
Laura Marroqui
Maikel L. Colli
Lorella Marselli
Raghavendra G. Mirmira
Piero Marchetti
Decio L. Eizirik
Publikationsdatum
05.01.2018
Verlag
Springer Berlin Heidelberg
Erschienen in
Diabetologia / Ausgabe 3/2018
Print ISSN: 0012-186X
Elektronische ISSN: 1432-0428
DOI
https://doi.org/10.1007/s00125-017-4536-4

Weitere Artikel der Ausgabe 3/2018

Diabetologia 3/2018 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.